表紙
市場調査レポート

米国の癌診断市場:売上高の予測、サプライヤーの市場シェア、競争戦略

2016-2020 US Emerging Tumor Marker Testing Market: Emerging Opportunities and Growth Strategies for Instrument and Reagent Suppliers

発行 Venture Planning Group 商品コード 278774
出版日 ページ情報 英文 620 Pages
納期: 即日から翌営業日
価格
こちらの商品の販売は終了いたしました。
Back to Top
米国の癌診断市場:売上高の予測、サプライヤーの市場シェア、競争戦略 2016-2020 US Emerging Tumor Marker Testing Market: Emerging Opportunities and Growth Strategies for Instrument and Reagent Suppliers
出版日: ページ情報: 英文 620 Pages

当商品の販売は、2016年06月27日を持ちまして終了しました。

概要

当レポートでは、米国におけるがん診断の関連市場における今後の市場機会について分析し、現在・将来の診断検査の動向や、各種診断技術の潜在的用途、主な試薬の分野別の売上高見通し(今後5年間分)、主要企業のプロファイル、代替的な事業拡張戦略などを調査・考察して、その結果を概略以下の構成でお届けします。

第1章 イントロダクション

第2章 世界の市場・技術の概要

  • 癌の統計データと病因
    • 乳癌
    • 肺癌
    • 結腸・直腸癌
    • 前立腺癌
    • 胃癌
    • 白血病
    • リンパ腫
    • 口腔癌
    • 皮膚癌
    • 子宮癌
    • 卵巣癌
    • 膀胱癌
  • 既存・新規の主な癌診断検査(全33種)
  • 診断装置のレビューと市場ニーズ
  • 既存・新規の診断技術
    • モノクローナル/ポリクローナル抗体
    • 免疫学的検定
    • 分子診断
    • 染色体分析
    • 人工知能
    • フローサイトメトリー
    • 二次元ゲル電気泳動(2-DGE)
    • バイオセンサー
    • 競合・補完技術
  • 個人向け検査

第3章 米国市場

  • エグゼクティブ・サマリー
  • ビジネス環境
  • 市場構造
  • 市場規模・成長率、主要サプライヤーの売上高と市場シェア

第4章 主な製品開発機会

  • 試薬キットと検査システム/パネル
  • 機器
  • コンピューター、ソフトウェア、オートメーション
  • 補助製品

第5章 分散検査製品の設計基準

第6章 代替的な市場普及戦略

  • 内部開発
  • 共同事業協定
  • 大学との契約
  • 流通戦略
    • マーケティングのアプローチ
    • 製品の複雑性
    • 顧客の選好
    • 既存のサプライヤー
    • 新規参入サプライヤー
    • 流通業者の主な種類
    • 市場の分類

第7章 潜在的な市場参入障壁とリスク

  • 市場の成熟化
  • コスト抑制
  • 競争
  • 最先端技術とその限界
  • 特許保護
  • 規制による抑制
  • 分散型検査市場の課題

第8章 競合企業プロファイル

  • Abbott
  • AdnaGen
  • Agilent Technologies
  • Applied Gene Technologies
  • Arca/Nuvelo
  • Beckman Coulter/Danaher
  • Becton Dickinson
  • Biomedical Diagnostics
  • bioMerieux
  • Bio-Rad
  • CellSearch
  • Cepheid
  • Correlogic Systems/Vermillion
  • Decode
  • Diadexus
  • Diagnocure
  • Diasorin
  • 栄研化学
  • Epigenomics
  • Enterix
  • Enzo Biochem
  • Exact Sciences
  • 富士レビオ/Innogenetics
  • Guided Therapeutics
  • Hologic/Gen-Probe
  • Kreatech
  • 協和メデックス
  • Life Technologies
  • Mackay Life Sciences
  • Myriad Genetics
  • Nanogen Elitech
  • OncoLab
  • Ortho-Clinical Diagnostics
  • Panacea Pharmaceuticals
  • Polartechnics
  • Polymedco
  • PreMD
  • Qiagen/Ipsogen
  • Quest Diagnostics
  • Radient Pharmaceuticals
  • Roche
  • Scienion
  • Sequenom
  • Siemens Healthcare
  • タカラバイオ
  • Targeted Diagnostics & Therapeutics
  • 東ソー
  • Veridex
  • 和光純薬工業
  • Wallac/PE
  • Zila

第9章 付録

  • 付録I:癌診断技術とその活用方法を開発している主な大学・研究機関
  • 付録II:為替レートの予測値

図表一覧

目次
Product Code: VPTM17000

Highlights

  • Comprehensive 620-page analysis of the US tumor marker testing market.
  • Major issues pertaining to the US laboratory practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the next five years.
  • Mortality statistics and scientific views on the etiology of major types of cancer, e.g., lung, colorectal, breast, prostatic, pancreatic, leukemia, lymphoma, gastrointestinal, bladder, liver, ovarian, testicular, oral, skin and others.
  • Five-year test volume and sales forecasts over for 40 tumor marker performed in US hospitals, commercial laboratories and physician offices.
  • Placements and installed base of automated and semi-automated analyzers used for tumor marker testing.
  • Current instrumentation technologies and feature comparison of leading analyzers.
  • Sales and market shares of leading suppliers.
  • Emerging diagnostic technologies and their potential market applications.
  • Product development opportunities.
  • Profiles of current and emerging suppliers, including their sales, market shares, product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements and business strategies.
  • Business opportunities and strategic recommendations for suppliers.

Contains 620 pages and 103 tables

Table of Contents

I. Introduction

II. Worldwide Market and Technology Overview

  • A. Cancer Statistics and Etiology
    • 1. Breast Cancer
    • 2. Lung Cancer
    • 3. Colon and Rectum Cancer
    • 4. Prostate Cancer
    • 5. Stomach Cancer
    • 6. Leukemia
    • 7. Lymphoma
    • 8. Oral Cancer
    • 9. Skin Cancer
    • 10. Uterine Cancer
    • 11. Ovarian Cancer
    • 12. Bladder Cancer
  • B. Major Current And Emerging Cancer Diagnostic Tests
    • 1. Introduction
    • 2. Tumor Marker Classification
    • 3. ACTH
    • 4. Alpha-Fetoprotein (AFP)
    • 5. Beta-2 Microglobulin
    • 6. CA 15-3/27.29
    • 7. CA 19-9
    • 8. CA-125
    • 9. Calcitonin
    • 10. Carcinoembrionic Antigen (CEA)
    • 11. Estrogen and Progesterone Receptors
    • 12. Ferritin
    • 13. Gastrin
    • 14. Human Chorionic Gonadotropin (HCG)
    • 15. Insulin
    • 16. NSE
    • 17. Occult Blood
    • 18. PAP Smear/HPV
    • 19. Prostatic Acid Phosphatase (PAP)
    • 20. Prostate-Specific Antigen (PSA)
    • 21. Squamous Cell Carcinoma Antigen (SCC)
    • 22. T and B Lymphocytes
    • 23. TdT
    • 24. Thyroglobulin
    • 25. Tissue Polypeptide Antigen (TPA)
    • 26. Biochemical Tumor Markers
      • ADA
      • B-Protein
      • PNP
      • 5'-Nucleotidase
    • 27. Oncogenes
      • Abl/abl-bcr
      • AIB1
      • BCL-2
      • BRCA1
      • CD44
      • C-fos
      • C-myb
      • C-myc
      • CYP-17
      • Erb-B
      • HPC1
      • N-myc
      • P40
      • P51
      • P53
      • PIK3CA
      • PTI-1
      • Ras
      • Reg
      • Sis
      • Src
    • 28. Polypeptide Growth Factors
      • Basic Fibroblast Growth Factor
      • Beta-TGF
      • Cachectin (TNT)
      • Calmodulin
      • ECFR
      • Nerve Growth Factor (NGF)
      • Epidermal Growth Factor (EGF)
      • Ornithine Decarboxylase
      • Transferrin
      • Transforming Growth Factor-Alpha
    • 29. Ectopic Hormones
    • 30. Colony Stimulating Factors
    • 31. Lymphokines
      • Alpha-Interferon
      • B Cell Growth Factors
      • B Cell Growth Factor (BCGF)
      • Gamma-Interferon
      • Interleukin-1 (IL-1)
      • Macrophage Activating Factor
    • 32. Immunohistochemical Stains
    • 33. Emerging Tumor Markers
      • N-Acetylglucosamine
      • Actin
      • Alpha-Actin
      • Antineuronal Antibodies
      • 7B2
      • B72.3
      • Bax
      • BCD-F9
      • BLCA-4
      • Blood Group Antigens A,B,H
      • CA 50
      • CA 72-4/TAG-72
      • CA 195
      • CA-242
      • CA-549
      • CAM 26
      • CAR-3
      • Cathepsin-D
      • Chromogranin A and B
      • Cluster 1 Antigen
      • Cluster-5/5A Antigen
      • CTA
      • CU18
      • DR-70
      • DU-PAN-2
      • Endometrial Bleeding Associated Factor
      • Endostatin
      • Epithelial Membrane Antigen
      • Feulgen Hydrolysis
      • Fibronectin
      • FSH
      • (1->3)-L-fucosyltransferase
      • Gastrin-Releasing Peptide (GRP)
      • GDCFP-15
      • Glucagon
      • Glycoamines
      • H23
      • Her-2
      • Human Carcinoma Antigen
      • HPA
      • HSP27
      • Intermediate Filaments
      • Cytokeratins/CK18/Cyfra 21-1
      • Desmin
      • Gliofibrillary Acid Protein
      • Neurofilaments
      • Vimentin
      • KA 93
      • Kinases
      • KP16D3
      • LAI
      • Leukocyte Common Antigen
      • Lewis Antigens
      • Lysophosphatidic Acid (LPA)
      • Ma 695/Ma 552
      • MABDF3
      • MAG
      • ME1
      • Minactivin
      • MN/CA9
      • MSA
      • Mucin Cancer Antigen (MCA)
      • Multiple Tumor Suppressor 1
      • Myosin
      • NEA-130
      • NMP22
      • OA-519
      • Opiod Peptides
      • P-glycoprotein
      • Pancreatic Oncofetal Antigen (POA)
      • Placental Lactogen
      • PR92
      • Proliferative Index, Ki-67
      • Px
      • RB Inactivation/Deletion
      • Ret
      • SCCL 175
      • Selectin
      • Sialic Acid
      • Sialyl SSEA-1/SLX
      • SN10
      • Somatostatin
      • TA-90
      • TABA
      • Tachykinin
      • TAG 12
      • TPS
      • Troponin
      • Tubulin
      • VCAM
      • VEGF
      • Villen
  • C. Instrumentation Review And Market Needs
  • D. Current and Emerging Technologies
    • 1. Monoclonal and Polyclonal Antibodies
    • 2. Immunoassays
      • a. Technological Principle
      • b. Radioimmunoassay (RIA)
      • c. Enzyme Immunoassays (EIA)
        • Overview
        • ELISA
        • Immunofiltration
        • Particle-Membrane Capture Immunoassay
        • Enzyme Amplification
      • d. Fluorescent Immunoassays
      • e. Luminescence
        • Chemiluminescence
        • Bioluminescence
      • f. Latex Agglutination
      • g. Immunoprecipitation
      • h. Affinity Chromatographu
      • e. Liposome Flow-Injection Immunoassay
    • 3. Molecular Diagnostics
      • a. Technology Overview
      • b. Amplification Methods
    • 4. Chromosome Analysis
      • a. Chronic Myelogenous Leukemia (CML)
      • b. Acute Myeloid Leukemia (AML)
      • c. Acute Lymphoblastic Leukemia (ALL)
      • d. Malignant Lymphomas Lymphoid Malignancies
      • e. Chronic Lymphocytic Leukemia (CLL)
      • f. Solid Cancers
      • g. Chromosomal Translocation and Oncogenes
    • 5. Artificial Intelligence
    • 6. Flow Cytometry
    • 7. Two Dimensional Gel Electrophoresis (2-DGE)
    • 8. Biosensors
    • 9. Competing/Complementing Technologies
      • a. CT
      • b. MRI
      • c. NMR
      • d. PET
      • e. Photonics Spectroscopy
  • G. Personal Testing

III. U.S.A.

  • A. Executive Summary
  • B. Business Environment
  • C. Market Structure
  • D. Market Size, Growth and Major Suppliers Sales and Market Shares

X. Major Product Development Opportunities

  • A. Reagent Kits and Test Systems/Panels
  • B. Instrumentation
  • C. Computers, Software and Automation
  • D. Auxiliary Products

XI. Design Criteria for Decentralized Testing Products

XII. Alternative Market Penetration Strategies

  • A. Internal Development
  • B. Collaborative Arrangements
  • C. University Contracts
  • D. Distribution Strategies
    • 1. Marketing Approaches
    • 2. Product Complexity
    • 3. Customer Preference
    • 4. Established Suppliers
    • 5. Emerging Suppliers
    • 6. Major Types of Distributors
    • 7. Market Segmentation Factor

XIII. Potential Market Entry Barriers and Risks

  • A. Market Maturity
  • B. Cost Containment
  • C. Competition
  • D. Technological Edge and Limitations
  • E. Patent Protection
  • F. Regulatory Constraints
  • G. Decentralized Testing Market Challenges

XIV. Competitive Profiles

  • Abbott
  • AdnaGen
  • Agilent Technologies
  • Applied Gene Technologies
  • Arca/Nuvelo
  • Beckman Coulter/Danaher
  • Becton Dickinson
  • Biomedical Diagnostics
  • bioMerieux
  • Bio-Rad
  • CellSearch
  • Cepheid
  • Correlogic Systems/Vermillion
  • Decode
  • Diadexus
  • Diagnocure
  • Diasorin
  • Eiken Chemical
  • Epigenomics
  • Enterix
  • Enzo Biochem
  • Exact Sciences
  • Fujirebio/Innogenetics
  • Guided Therapeutics
  • Hologic/Gen-Probe
  • Kreatech
  • Kyowa Medex
  • Life Technologies
  • Mackay Life Sciences
  • Myriad Genetics
  • Nanogen Elitech
  • OncoLab
  • Ortho-Clinical Diagnostics
  • Panacea Pharmaceuticals
  • Polartechnics
  • Polymedco
  • PreMD
  • Qiagen/Ipsogen
  • Quest Diagnostics
  • Radient Pharmaceuticals
  • Roche
  • Scienion
  • Sequenom
  • Siemens Healthcare
  • Takara Bio
  • Targeted Diagnostics & Therapeutics
  • Tosoh
  • Veridex
  • Wako Pure Chemicals
  • Wallac/PE
  • Zila

XV. Appendixes:

  • Appendix I: Major Universities and Research Centers Developing Cancer Diagnostic Technology and Applications
  • Appendix II: Assumed Currency Exchange Rates

List of Tables

  • Tumor Marker Classification
  • Major Companies Developing or Marketing ACTH Tests
  • Major Companies Developing or Marketing AFP Tests
  • Major Companies Developing or Marketing Beta-2 Microglobulin Tests
  • Major Companies Developing or Marketing CA 15-3/27.29 Tests
  • Major Companies Developing or Marketing CA 19-9 Tests
  • Major Companies Developing or Marketing CA 125 Tests
  • Major Companies Developing or Marketing Calcitonin Tests
  • Major Companies Developing or Marketing CEA Tests
  • Major Companies Developing or Marketing Estrogen Receptor Tests
  • Major Companies Developing or Marketing Progesterone Receptor Tests
  • Major Companies Developing or Marketing Ferritin Tests
  • Major Companies Developing or Marketing Gastrin Tests
  • Major Companies Developing or Marketing HCG Tests
  • Major Companies Developing or Marketing Insulin Tests
  • Major Companies Developing or Marketing NSE Tests
  • Major Companies Developing or Marketing Occult Blood Tests
  • Major Companies Developing or Marketing PAP Smear/HPV Tests
  • Major Companies Developing or Marketing PAP Tests
  • Major Companies Developing or Marketing PSA Tests
  • Major Companies Developing or Marketing Lymphocyte Subclassification Tests
  • Biochemical Markers Potential Applications In Cancer Diagnosis
  • Oncogenes Potential Applications In Cancer Diagnosis
  • Major Companies Developing or Marketing Oncogene Tests
  • Growth Factors Potential Applications In Cancer Diagnosis
  • Colony Stimulating Factors Potential Applications in Cancer Diagnosis
  • Lymphokines Potential Applications In Cancer Diagnosis Immunohistochemical Stains Potential
  • Applications in Cancer Diagnosis
  • Executive Summary Table: U.S., Total Tumor Marker Test Volume and Sales Forecast By Market Segment
  • U.S., Estimated New Cancer Cases and Deaths
  • U.S., Estimated Cancer Death Rates Per 100,000 Population
  • U.S., Laboratories Performing Tumor Marker Tests by Market Segment
  • U.S., Hospital Laboratories Performing Tumor Marker Tests by Bed Size
  • U.S., Commercial/Private Laboratories Performing Tumor Marker Tests By Annual Test Volume
  • U.S., Physician Office Laboratories Performing Tumor Marker Tests By Practice Size
  • U.S., Total Tumor Marker Test Volume Forecast by Market Segment
  • U.S., All Market Segments Major Tumor Marker Test Volume Forecast
  • U.S., Hospital Laboratories Major Tumor Marker Test Volume Forecast by Test
  • U.S., Commercial/Private Laboratories Major Tumor Marker Test Volume Forecast
  • U.S., Physician Offices/Group Practices Major Tumor Marker Test Volume Forecast
  • U.S., Cancer Clinics Major Tumor Marker Test Volume Forecast by Test
  • U.S., Total Tumor Marker Sales Forecast by Market Segment
  • U.S., All Market Segment Major Tumor Marker Sales Forecast by Test
  • U.S., Hospital Laboratories Major Tumor Marker Sales Forecast by Test
  • U.S., Commercial/Private Laboratories Major Tumor Marker Sales Forecast by Test
  • U.S., Physician Offices/Group Practices Major Tumor Marker Sales Forecast by Test
  • U.S., Cancer Clinics Major Tumor Marker Sales Forecast by Test
  • U.S., ACTH Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., AFP Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., Beta-2 Microglobulin Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., CA 15-3/27.29 Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., CA 19-9 Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., CA-125 Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., Calcitonin Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., Cathepsin Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., CEA Test Volume and Diagnostics Sales by Market Segment
  • U.S., Chromogranin Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., Colon-specific Antigen Test Volume And Diagnostics Sales Forecast by Market Segment
  • U.S., Cytokeratins Test Volume And Diagnostics Sales Forecast by Market Segment
  • U.S., Estrogen Receptor Test Volume And Diagnostics Sales Forecast by Market Segment
  • U.S., Ferritin Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., Gastrin Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., HCG Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., Insulin Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., Interferons Test Volume And Diagnostics Sales Forecast by Market Segment
  • U.S., Interleukins Test Volume And Diagnostics Sales Forecast by Market Segment
  • U.S., Lymphocyte Subtyping Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., NSE Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., Nucleolar Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., Occult Blood Test Volume And Diagnostics Sales Forecast by Market Segment
  • U.S., Oncogenes Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., Pancreatic Oncofetal Antigen Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., PAP Smear Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., Parathyroid Hormone Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., Progesterone Receptor Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., PAP Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., PSA Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., S-100 Protein Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., Serotonin Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., Sialic Acid Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., Squamous Cell Carcinoma Antigen Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., TDT Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., Thymidine Kinase Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., Thyroglobulin Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., TPA Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., Total Tumor Marker Sales By Major Supplier
  • U.S., ACTH Testing Market Diagnostics Sales by Major Supplier
  • U.S., AFP Testing Market Diagnostics Sales by Major Supplier
  • U.S., Beta-2 Migroblolulin Testing Market Diagnostics Sales by Major Supplier
  • U.S., CA 15-3/27.29 Testing Market Diagnostics Sales by Major Supplier
  • U.S., CA 19-9 Testing Market Diagnostics Sales by Major Supplier
  • U.S., CA 125 Testing Market Diagnostics Sales by Major Supplier
  • U.S., CEA Testing Market Diagnostics Sales by Major Supplier
  • U.S., Ferritin Testing Market Diagnostics Sales by Major Supplier
  • U.S., HCG Testing Market Diagnostics Sales by Major Supplier
  • U.S., Insulin Testing Market Diagnostics Sales by Major Supplier
  • U.S., Parathyroid Hormone Testing Market Diagnostics Sales by Major Supplier
  • U.S., PAP Testing Market Diagnostics Sales by Major Supplier
  • U.S., Progesterone Receptor Testing Market Diagnostics Sales by Major Supplier
  • U.S., PSA Testing Market Diagnostics Sales by Major Supplier
Back to Top